NCT05363215View on ClinicalTrials.gov

A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 10, 2022

Primary Completion Date

April 12, 2023

Study Completion Date

April 12, 2023

Conditions
Renal Impairment
Interventions
DRUG

S-217622

Tablet for oral administration

Trial Locations (4)

32809

Orlando Clinical Research Center, Inc., Orlando

33014

Clinical Pharmacology of Miami, LLC, Miami

33147

Advanced Pharma CR, LLC, Miami

55114

Nucleus Network, Saint Paul

Sponsors

Lead Sponsor

Shionogi
All Listed Sponsors
lead

Shionogi

INDUSTRY

NCT05363215 - A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants | Biotech Hunter | Biotech Hunter